Archive for the ‘Clinical Trials / Drug Trials’ Category
Saturday, May 17th, 2008
- Five Oral Presentations at ASCO Annual Meeting Will Further Demonstrate the Strength of VELCADE Combinations in Front-line Multiple Myeloma -CAMBRIDGE, Mass., May 16, 2008 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced that new data from VELCADE clinical studies are scheduled to be featured at the 2008 ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
MONTVALE, N.J., May 16, 2008 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound's CNS activity in humans. In addition, the ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
WAYNE, Pa.--(BUSINESS WIRE)--May 16, 2008 - With the increased incidence of systemic fungal infections and the growing number of antifungal agents, laboratory methods to guide the selection of antifungal therapy have gained greater attention. Clinical and Laboratory Standards Institute (CLSI) has recently published an updated standard, Reference Method for Broth ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
First and Only Therapy Approved to Treat Both Type 2 Diabetes and High LDL- CholesterolPARSIPPANY, N.J., May 16, 2008 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced today that data from two pooled analyses further demonstrate that Welchol(TM) (colesevelam HCl), in combination with metformin- or sulfonylurea- based therapy, significantly lowers blood ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
WAYNE, N.J. and EMERYVILLE, Calif., May 16, 2008 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced more than 40 data presentations at the 2008 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the potential for Nexavar(R) (sorafenib) tablets in multiple tumor types as a single ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 16, 2008 - Amgen (NASDAQ:AMGN) today announced it will present new data from the Company's oncology portfolio on both approved and investigational cancer therapies at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting that will be held in Chicago from May 30 to June ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 16, 2008 - Genentech, Inc. (NYSE:DNA) today provided an overview of several clinical studies of Avastin(R) in multiple types of cancer that will be presented during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 30 to June 3 ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
BERKELEY, Calif.--(BUSINESS WIRE)--May 16, 2008 - Dynavax Technologies Corporation (Nasdaq:DVAX) today reported primary endpoint data from a chamber study of TOLAMBA(TM) that showed a measurable clinical benefit, reducing total nasal symptom score (TNSS) by 41% vs. placebo in 253 patients in the intent-to-treat population (p=0.09) and by 51% vs. placebo ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
NEW YORK--(BUSINESS WIRE)--May 16, 2008 - Pfizer announced today that study results across several difficult-to-treat cancers will be presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3, 2008. Pfizer will hold two briefings for journalists on June 1 and ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
- Data demonstrates safety and efficacy of first FDA-approved nebulized formoterol fumarate in patients with moderate to severe COPD -NAPA, Calif., May 16, 2008 /PRNewswire/ -- Dey, L.P. announced today that three clinical data presentations will be given at the International Conference of the American Thoracic Society (ATS) on May ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
NEW YORK--(BUSINESS WIRE)--May 16, 2008 - ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that significant scientific data on ERBITUX(R) (cetuximab) will be presented at the American Society of Clinical Oncology (ASCO) 2008 Annual Meeting taking place ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
NEW YORK--(BUSINESS WIRE)--May 16, 2008 - ImClone Systems Incorporated (NASDAQ: IMCL) today announced data from the Phase II OPUS study that show that the addition of ERBITUX(R) (cetuximab) to FOLFOX chemotherapy significantly improves both response rate and progression-free survival over FOLFOX alone in the first-line treatment of metastatic colorectal cancer ...
Posted in Clinical Trials / Drug Trials | No Comments »
Saturday, May 17th, 2008
BOTHELL, Wash.--(BUSINESS WIRE)--May 16, 2008 - Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that SGN-35 phase I clinical data will be presented during a poster discussion session at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 to June 3, 2008 at the McCormick Place ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, May 16th, 2008
The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, May 16th, 2008
Schering-Plough Corporation (NYSE: SGP), a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced that data from several clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy, as well as boceprevir, the company's investigational oral HCV protease inhibitor, ...
Posted in Clinical Trials / Drug Trials | No Comments »